Japan based Santen Pharmaceutical Co., Ltd. and Singapore based Plano Pte. Ltd have announced a strategic alliance to tackle the global burden of myopia.

Under this strategic alliance, Plano has secured an investment from Santen. Santen, through Plano, will initiate to tackle the burden of myopia using both a holistic approach and innovative technological solutions.

Santen, as a leading company in the field of ophthalmology, has cultivated expertise and capabilities specializing in ophthalmology based on a thorough customer orientation, including patients and healthcare professionals. 

Plano is an eye health tech company launched in 2017, founded by Associate Professor Mohamed Dirani. It is the first spin-off from the Singapore Eye Research Institute (SERI) - Singapore National Eye Centre (SNEC) Ophthalmic Technologies Incubator Programme, dedicated to accelerating highly promising ophthalmic R&D projects towards commercialisation and medical deployment. 

The key products in the company's ecosystem include the plano application and the online optometry booking system, Plano Eyecheck. The science-based plano application has been adopted by more than 250,000 households. In less than 3 years, Plano is considered as one of the world leaders in raising awareness and educating the public on the prevention, detection and risk factors of myopia.